• Overview
  • Eligibility
  • More info
  • Locations

A Phase II Study of Newly Diagnosed Patients With BCR/ABL (+) Chronic Myelogenous Leukemia Treated With Combined Homoharringtonine (NSC #141633) and Low-Dose Cytarabine (NCT00003694)

Phase II trial to study the effectiveness of homoharringtonine plus low-dose cytarabine in treating patients who have newly diagnosed chronic phase chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
  • Drug: omacetaxine mepesuccinate
    Given IV
    • CGX-635
    • homoharringtonine
  • Drug: cytarabine
    Given IV
    • ARA-C
    • arabinofuranosylcytosine
    • arabinosylcytosine
    • Cytosar-U
    • cytosine arabinoside
  • Other: laboratory biomarker analysis
    Correlative studies
    Ages eligible for Study
    16 Years and older
    Genders eligible for Study
    Accepts Healthy Volunteers

    I. To estimate the hematologic and cytogenetic response rate of newly diagnosed patients with BCR/ABL (+) chronic myelogenous leukemia (CML) treated with combined homoharringtonine (omacetaxine mepesuccinate) and low dose cytarabine.

    II. To estimate the toxicity of these two drugs given in combination in a cooperative group setting.


    I. To assess duration of hematological response and incidence of hematological progression for all patients.

    II. To assess duration of cytogenetic response in patients continuing protocol therapy beyond the initial nine months.

    III. To use quantitative Southern blot monitoring of blood samples to monitor molecular response rates in patients entered onto CALGB treatment studies for CML.

    IV. To compare quantitative Southern blot results of blood samples with marrow cytogenetics at the time of complete molecular response.

    V. To use RT-PCR to monitor the frequency of residual disease in patients who have achieved a complete blood Southern blot and marrow cytogenetic response (elimination of BCR/ABL positivity by Southern blot and absence of the Philadelphia chromosome by cytogenetics).


    Patients receive cytarabine and homoharringtonine concurrently by continuous intravenous infusion for 7 days. Courses repeat every 28 days. Patients receive a minimum of 9 courses of therapy in the absence of disease progression and unacceptable toxicity. Patients who are major cytogenetic responders at 9 months may continue therapy or switch to interferon. Minor cytogenetic responders are switched to interferon, and nonresponders are removed from therapy and given the option to switch to interferon.

    Patients are followed every 6 months for 10 years.

    1 locations

    United States (1)
    • Dana-Farber Harvard Cancer Center
      Not specified
      Boston, Massachusetts, United States, 02115
    28 February, 1999
    03 June, 2013
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!